Protocol Review Monitoring System The goal of the Protocol Review and Monitoring System (PRMS) is to promote the conduct of scientifically meritorious clinical research under the aegis of the UCSD Cancer Center. The mechanism for accomplishing this is the establishment of a Protocol Review and Monitoring Committee (PRMC). The PRMC is a multidisciplinary standing committee of the Moores Cancer Center. Its charge is the scientific peer review of research studies involving patients with cancer that are conducted at UCSD or its affiliate institutions, the Veterans Administration Healthcare System San Diego and Children's Hospital San Diego. To provide this oversight function, the PRMC has the following Specific Objectives: (1) perform scientific peer review of cancer-related clinical and translational research protocols to be conducted at UCSD and affiliate institutions;(2) approve a priority designation for new cancer clinical protocols in coordination with leaders of the Cancer Center's disease-focused Specialized Cancer Units;(3) review the scientific progress of active clinical protocols through annual evaluation of subject accrual data;and (4) review in real-time those serious and unexpected adverse events that meet criteria for reporting to the UCSD Institutional Review Board (IRB). The PRMC is granted authority by the Cancer Center Director to approve the initiation and continuation of clinical cancer research protocols, or to recommend their termination according to defined review and monitoring criteria. In concert with these scientific review and monitoring functions, the PRMC directly informs the UCSD IRB of relevant scientific and subject safety issues for complementary review by that committee of cancer-related research submitted for activation at UCSD and affiliate institutions. Both the PRMC Chair and Vice Chair are members of the UCSD IRB, and approval by PRMC is required for the activation of cancer-related research at UCSD and its affiliates. In achieving its scientific review and monitoring objectives, the PRMC ensures that Cancer Center resources are effectively utilized to foster clinical cancer research that is of high scientific quality and importance.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA023100-25
Application #
7918257
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-05-01
Budget End
2010-04-30
Support Year
25
Fiscal Year
2009
Total Cost
$193,713
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Nguyen, Vi; Marmor, Rebecca A; Ramamoorthy, Sonia L et al. (2018) The Use of Solicited Publishing by Academic Surgeons. Surgery 164:212-218
Yan, Wei; Wu, Xiwei; Zhou, Weiying et al. (2018) Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. Nat Cell Biol 20:597-609
Pandolfi, Erica C; Hoffmann, Hanne M; Schoeller, Erica L et al. (2018) Haploinsufficiency of SIX3 Abolishes Male Reproductive Behavior Through Disrupted Olfactory Development, and Impairs Female Fertility Through Disrupted GnRH Neuron Migration. Mol Neurobiol 55:8709-8727
Galanina, Natalie; Goodman, Aaron M; Cohen, Philip R et al. (2018) Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade. Cancer Immunol Res 6:1129-1135
Chin, Andrew R; Yan, Wei; Cao, Minghui et al. (2018) Polarized Secretion of Extracellular Vesicles by Mammary Epithelia. J Mammary Gland Biol Neoplasia 23:165-176
Garcia, Daniel A; Baek, Christina; Estrada, M Valeria et al. (2018) USP11 Enhances TGF?-Induced Epithelial-Mesenchymal Plasticity and Human Breast Cancer Metastasis. Mol Cancer Res 16:1172-1184
Jiang, Qingfei; Jamieson, Catriona (2018) BET'ing on Dual JAK/BET Inhibition as a Therapeutic Strategy for Myeloproliferative Neoplasms. Cancer Cell 33:3-5
Ramirez, Oscar; Aristizabal, Paula; Zaidi, Alia et al. (2018) Implementing a Childhood Cancer Outcomes Surveillance System Within a Population-Based Cancer Registry. J Glob Oncol :1-11
Liu, Liang; Yang, Lin; Yan, Wei et al. (2018) Chemotherapy Induces Breast Cancer Stemness in Association with Dysregulated Monocytosis. Clin Cancer Res 24:2370-2382
Lwin, Thinzar M; Murakami, Takashi; Miyake, Kentaro et al. (2018) Tumor-Specific Labeling of Pancreatic Cancer Using a Humanized Anti-CEA Antibody Conjugated to a Near-Infrared Fluorophore. Ann Surg Oncol 25:1079-1085

Showing the most recent 10 out of 862 publications